medac
Diagnostika



p40 (ΔNp63-Isoform)

wichtiger Marker zur Diagnostik von

- **Lungen- (PlattenepithelCa)**
- **Mamma- (Myoepithelzellen)**
- **Prostata- (Basalzellen)**
- **Blasenkarzinomen**

- **spezifischer als p63**
- **eindeutige Unterscheidung** Plattenepithelkarzinom-Adenokarzinom (Lunge)
- **sichere Diagnosen**, auch an kleinen Biopsien
- **Lungen-Panel:**
  - AdenoCa: **TTF-1** (nukleär), **Napsin A** (zytoplasmatisch)
  - PlattenepithelCa: **p40** (nukleär), **CK5** (zytoplasmatisch), **Desmoglein-3** (membranös)
- p40 (Kaninchen, polyklonal) empfohlen in wichtigen NSCLC Schlüsselpublikationen[1-10]
- p40 wertvoller Marker für **Myoepithelzellen** (Mamma[14,15]) und **Basalzellen** (Prostata[16], Harnblase[17-20]), Lit. umseitig

Lungentumor	Napsin A* (MRQ-60) neu	TTF-1 (8G7G3/1)	CK5** (EP1601Y)	p63 (4A4)	Desmoglein-3 (5G11) neu	p40 (polyklonal)# neu
AdenoCa (gut differenziert)	+	+	–	-/+	-	–
AdenoCa (gering differenziert)	+	–	–	-/+	-	–
Neuroendokrin (CD56+)	–	+	–	–	-	–
PlattenepithelCa	–	–	+	+	+	+

* sensitivster AdenoCa-Marker der Lunge (Sensitivität 83%, Spezifität 98%), Whithaus K, *et al.* Arch Pathol Lab Med 2012; 136:155-162.
** alternativ: CK14, # affinitätsisoliert

Referenzen p40
NSCLC

1. Bishop JA *et al.* p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-415.
2. Butnor KJ, Burchette JL. p40 (ΔNp63) and keratin 34βE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples. Hum Pathol 2013; 44: 1479-1486.
3. Nobre AR, *et al.* p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol 2013; 57: 1-8.
4. Nonaka D. A study of ΔNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012; 36: 895-899.
5. Pelosi G *et al.* ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cell blocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol 2012; 7: 281-290.
6. Pelosi G, *et al.* ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol 2013, 21: 229-239.
7. Rekhtman N, *et al.* Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2013; 26: 511-522.
8. Rekhtman N, *et al.* Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18: 1167-1176.
9. Travis WD, *et al.* Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 IASLC / ATS / ERS classification. Arch Pathol Lab Med 2013; 137: 668-684.
10. Travis WD, *et al.* Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 IASLC / ATS / ERS classification. Arch Pathol Lab Med 2013;137: 685-705.

medac
Gesellschaft für klinische Spezialpräparate mbH • Diagnostika • Theaterstrasse 6 • D-22880 Wedel
Telefon 04103/8006-342 • Fax 04103/8006-359 • www.medac-diagnostika.de • diagnostika@medac.de

11. Ao MH *et al.* The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol 2014; 45: 926-934.
12. Collins BT, *et al.* Utilization of p40 (ΔNp63) with p63 and cytokeratin 5/6 immunohistochemistry in non-small cell lung carcinoma fine-needle aspiration biopsy. Acta Cytol 2013;57:619-624.
13. Tatsumori T, *et al.* p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and Sox2. Appl Immunohistochem Mol Morphol 2014; 22: 377-382.

Mamma

14. Barbareschi M, *et al.*p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001; 25: 1054-1060.
15. Kim SK, *et al.* p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry. Int J Clin Exp Pathol 2014; 7: 1032-1041.

Prostata

16. Sailer V, *et al.* Comparison of p40 (ΔNp63) and p63 expression in prostate tissues - which one is the superior diagnostic marker for basal cells? Histopathology 2013; 63: 50-56.

Harnblase (und alle Plattenepithelkarzinome)**:**

17. Gailey MP,Bellizzi AM. Immunohistochemistry for the novel markers glypican-3, Pax8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma. Am J Clin Pathol 2013; 140: 872-880.
18. Brandler TC, *et al.* Usefulness of GATA3 and p40 immunostains in the diagnosis of metastatic urothelial carcinoma in cytology specimens. Cancer Cytopathol 2014, in press.
19. Karni-Schmidt O, *et al.* Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011; 178: 1350-1360.
20. Ho PL, *et al.* Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 2012; 9: 583-594.

Bestell-Information Tel. 04103/8006-111

Antikörper	Klon	Spezies	Verdünnung	konzentriert 0,1 ml	konzentriert 0,5 ml	konzentriert 1,0 ml	gebrauchsfertig / RTU 1 ml	gebrauchsfertig / RTU 7 ml	gebrauchsfertig / RTU 6 ml
CD56	MRQ-42	Kaninchen	100-500	156R-94	156R-95	156R-96	156R-97	156R-98	-
CD56	123C3.D5	Maus	100-500	156M-84	156M-85	156M-86	156M-87	156M-88	-
CK5	EP1601Y	Kaninchen	50-200	305R-14	305R-15	305R-16	305R-17	305R-18	-
CK5/6	D5/16B4	Maus	50-200	356M-14	356M-15	356M-16	356M-17	356M-18	-
CK14	LL002	Maus	100-500	314M-14	314M-15	314M-16	314M-17	314M-18	-
CK14	SP53	Kaninchen	100-500	314R-14	314R-15	314R-16	314R-17	314R-18	-
Desmoglein-3	5G11	Maus	100	-	-	Z2279	-	-	-
GATA3	L50-823	Maus	100-500	390M-14	390M-15	390M-16	390M-17	390M-18	-
Napsin A	MRQ-60	Maus	100-500	352M-94	352M-95	352M-96	352M-97	352M-98	-
Napsin A	polyklonal	Kaninchen	100-500	352A-74	352A-75	352A-76	352A-77	352A-78	-
ΔNp63 (p40)	polyklonal	Kaninchen	50-100	-	RP 163-05	-	-	-	PDR055
ΔNp63 (p40)	ZR8	Kaninchen	100-200	-	-	Z2004	-	-	-
p63	4A4	Maus	100	-	-	Z2003L	-	-	413751F
Sox2*	SP76	Kaninchen	50-200	371R-14	371R-15	371R-16	371R-17	371R-18	-
TTF-1**	8G7G3/1	Maus	100-500	343M-94	343M-95	343M-96	343M-97	343M-98	-

* diffusse Überexpression im Plattenepithelkarzinomen; Stammzell- und Pluripotenz-Marker

** auch 15 ml RTU (343M-99) und 25 ml RTU (343M-90) lieferbar

Für weitere Marker fordern Sie den aktuellen Cell Marque Katalog sowie das dazugehörige Supplement an. Eine Literaturübersicht zum Vergleich von p63 und ΔNp63 (p40) finden Sie auf unserer Webseite unter „Information“ --> „Primär- und Sekundärantikörper“.

Informationen aus erster Hand
www.medac-diagnostika.de

medac
Gesellschaft für klinische Spezialpräparate mbH • Diagnostika • Theaterstrasse 6 • D-22880 Wedel
Telefon 04103/8006-342 • Fax 04103/8006-359 • www.medac-diagnostika.de • diagnostika@medac.de